Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2014

01-08-2014 | Clinical trial

Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival

Authors: Christian B. van der Pol, Mark E. Schweitzer, Gina Di Primio, Marcos L. Sampaio, Ania Kielar, Mark Clemons, Arash Jaberi

Published in: Breast Cancer Research and Treatment | Issue 3/2014

Login to get access

Abstract

The purpose of this study was to determine if bone metastasis characteristics on axial skeleton MRI are associated with either skeletal-related events (SREs) or survival in breast cancer patients. A retrospective review was performed on 247 breast cancer patients with bone metastases identified on axial skeleton MRI. MRI studies were reviewed for metastases T1 signal, signal uniformity, complete vertebral metastatic marrow replacement, metastases quantity, and distribution. Odds ratio (OR) and hazard ratios (HR) were calculated, with 95 % confidence intervals (95 % CI), to determine association with either future SREs or survival. At the time of analysis, 174 (70 %) patients had developed SREs and 176 (71 %) patients were dead. Features of skeletal metastases associated with SREs included the presence of complete metastatic marrow replacement within any vertebra; OR 2.363 (95 % CI 1.240–4.504, P = 0.0090), and more widely distributed metastases; OR 1.239 (95 % CI 1.070–1.435, P = 0.0040). Features associated with shorter survival included the presence of complete metastatic marrow replacement within any vertebra; HR 1.500 (95 % CI 1.105–2.036, P = 0.0093), and more widely distributed metastases; HR 1.141 (95 % CI 1.047–1.243, P = 0.0027). Metastases T1 signal, signal uniformity, and surprisingly quantity were not associated with SREs or survival. Axial skeleton MRI was able to identify characteristics predictive of future SREs and survival. These characteristics could be used for risk stratification for future trials if prospectively validated.
Literature
2.
go back to reference Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59:271–278PubMedCrossRef Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59:271–278PubMedCrossRef
3.
go back to reference Koenders PG, Beex LV, Kloppenborg PW, Smals AG, Benraad TJ (1992) Human breast cancer: survival from first metastasis. Breast cancer study group. Breast Cancer Res Treat 21:173–180PubMedCrossRef Koenders PG, Beex LV, Kloppenborg PW, Smals AG, Benraad TJ (1992) Human breast cancer: survival from first metastasis. Breast cancer study group. Breast Cancer Res Treat 21:173–180PubMedCrossRef
4.
go back to reference Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56:67–78PubMedCrossRef Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56:67–78PubMedCrossRef
5.
go back to reference Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205PubMed Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205PubMed
6.
go back to reference Yeatman TJ (1995) The natural history of locally advanced primary breast carcinoma and metastatic disease. Surg Oncol Clin N Am 4:569–589PubMed Yeatman TJ (1995) The natural history of locally advanced primary breast carcinoma and metastatic disease. Surg Oncol Clin N Am 4:569–589PubMed
7.
go back to reference Kuchuk I, Clemons M, Addison C (2012) Time to put an end to the “one size fits all” approach to bisphosphonate use in patients with metastatic breast cancer? Curr Oncol 19:e303–e304PubMedCentralPubMed Kuchuk I, Clemons M, Addison C (2012) Time to put an end to the “one size fits all” approach to bisphosphonate use in patients with metastatic breast cancer? Curr Oncol 19:e303–e304PubMedCentralPubMed
8.
go back to reference Clemons M, Gelmon KA, Pritchard KI, Paterson AHG (2012) Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol 19:259–268PubMedCentralPubMedCrossRef Clemons M, Gelmon KA, Pritchard KI, Paterson AHG (2012) Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol 19:259–268PubMedCentralPubMedCrossRef
9.
go back to reference Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29PubMedCentralPubMedCrossRef Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29PubMedCentralPubMedCrossRef
10.
go back to reference Costa L, Badia X, Chow E, Lipton A, Wardley A (2008) Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer 16:879–889PubMedCrossRef Costa L, Badia X, Chow E, Lipton A, Wardley A (2008) Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer 16:879–889PubMedCrossRef
11.
go back to reference Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174PubMedCrossRef Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174PubMedCrossRef
12.
go back to reference Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 123:767–779PubMedCrossRef Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 123:767–779PubMedCrossRef
13.
go back to reference Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M (2010) Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 18:197–203PubMedCrossRef Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M (2010) Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 18:197–203PubMedCrossRef
14.
go back to reference Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193–201PubMedCrossRef Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193–201PubMedCrossRef
15.
go back to reference DePuy V, Anstrom K, Castel L, Schulman K, Weinfurt K, Saad F (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869–876PubMedCrossRef DePuy V, Anstrom K, Castel L, Schulman K, Weinfurt K, Saad F (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869–876PubMedCrossRef
16.
go back to reference Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187PubMedCrossRef Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187PubMedCrossRef
17.
go back to reference Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat 129:495–503PubMedCrossRef Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat 129:495–503PubMedCrossRef
18.
go back to reference Eustace S, Tello R, DeCarvalho V et al (1997) A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR 169:1655–1661PubMedCrossRef Eustace S, Tello R, DeCarvalho V et al (1997) A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR 169:1655–1661PubMedCrossRef
19.
go back to reference Lauenstein TC, Goehde SC, Herborn CU et al (2004) Whole-body MR imaging: evaluation of patients for metastases. Radiology 233:139–148PubMedCrossRef Lauenstein TC, Goehde SC, Herborn CU et al (2004) Whole-body MR imaging: evaluation of patients for metastases. Radiology 233:139–148PubMedCrossRef
20.
go back to reference Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA (2004) Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 14:99–105PubMedCrossRef Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA (2004) Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 14:99–105PubMedCrossRef
21.
go back to reference Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M (2011) Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617PubMedCrossRef Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M (2011) Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617PubMedCrossRef
22.
go back to reference Yuh WT, Zachar CK, Barloon TJ, Sato Y, Sickels WJ, Hawes DR (1989) Vertebral compression fractures: distinction between benign and malignant causes with MR imaging. Radiology 172:215–218PubMedCrossRef Yuh WT, Zachar CK, Barloon TJ, Sato Y, Sickels WJ, Hawes DR (1989) Vertebral compression fractures: distinction between benign and malignant causes with MR imaging. Radiology 172:215–218PubMedCrossRef
24.
go back to reference Baker LL, Goodman SB, Perkash I, Lane B, Enzmann DR (1990) Benign versus pathologic compression fractures of vertebral bodies: assessment with conventional spin-echo, chemical-shift, and STIR MR imaging. Radiology 174:495–502PubMedCrossRef Baker LL, Goodman SB, Perkash I, Lane B, Enzmann DR (1990) Benign versus pathologic compression fractures of vertebral bodies: assessment with conventional spin-echo, chemical-shift, and STIR MR imaging. Radiology 174:495–502PubMedCrossRef
25.
go back to reference Noguchi M, Kikuchi H, Ishibashi M, Noda S (2003) Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 88:195–201PubMedCentralPubMedCrossRef Noguchi M, Kikuchi H, Ishibashi M, Noda S (2003) Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 88:195–201PubMedCentralPubMedCrossRef
26.
go back to reference Imbriaco M, Larson SM, Yeung HW et al (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 4:1765–1772PubMed Imbriaco M, Larson SM, Yeung HW et al (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 4:1765–1772PubMed
27.
go back to reference Sabbatini P, Larson SM, Kremer A et al (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17:948–957PubMed Sabbatini P, Larson SM, Kremer A et al (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17:948–957PubMed
28.
go back to reference Loeffler RK, DiSimone RN, Howland WJ (1975) Limitations of bone scanning in clinical oncology. JAMA 234:1228–1232PubMedCrossRef Loeffler RK, DiSimone RN, Howland WJ (1975) Limitations of bone scanning in clinical oncology. JAMA 234:1228–1232PubMedCrossRef
29.
go back to reference Brown AL, Middleton G, MacVicar AD, Husband JE (1998) T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol 53:493–501PubMedCrossRef Brown AL, Middleton G, MacVicar AD, Husband JE (1998) T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol 53:493–501PubMedCrossRef
30.
go back to reference Byun WM, Shin SO, Chang Y, Lee SJ, Finsterbusch J, Frahm J (2002) Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol 23:906–912PubMed Byun WM, Shin SO, Chang Y, Lee SJ, Finsterbusch J, Frahm J (2002) Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol 23:906–912PubMed
31.
go back to reference Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272PubMedCentralPubMedCrossRef Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272PubMedCentralPubMedCrossRef
32.
go back to reference Koizumi M, Yoshimoto M, Kasumi F, Ogata E (2003) Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 14:1234–1240PubMedCrossRef Koizumi M, Yoshimoto M, Kasumi F, Ogata E (2003) Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 14:1234–1240PubMedCrossRef
33.
go back to reference Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD (2001) Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 91:17–24PubMedCrossRef Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD (2001) Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 91:17–24PubMedCrossRef
34.
go back to reference Grankvist J, Fisker R, Iyer V et al (2012) MRI and PET/CT of patients with bone metastases from breast carcinoma. Eur J Radiol 81:e13–e18PubMedCrossRef Grankvist J, Fisker R, Iyer V et al (2012) MRI and PET/CT of patients with bone metastases from breast carcinoma. Eur J Radiol 81:e13–e18PubMedCrossRef
35.
go back to reference Costelloe CM, Madewell JE, Kundra V, Harrell RK, Bassett RL Jr, Ma J (2013) Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. Magn Reson Imaging 31:669–675PubMedCentralPubMedCrossRef Costelloe CM, Madewell JE, Kundra V, Harrell RK, Bassett RL Jr, Ma J (2013) Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. Magn Reson Imaging 31:669–675PubMedCentralPubMedCrossRef
Metadata
Title
Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival
Authors
Christian B. van der Pol
Mark E. Schweitzer
Gina Di Primio
Marcos L. Sampaio
Ania Kielar
Mark Clemons
Arash Jaberi
Publication date
01-08-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3046-z

Other articles of this Issue 3/2014

Breast Cancer Research and Treatment 3/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine